Skip to content

Nutritional Intervention With Tenebrio Molitor Powder in Children With Chronic Malnutrition in the Democratic Republic of the Congo

SANTE INITIATIVE: Nutritional Intervention With Tenebrio Molitor Powder in Children With Chronic Malnutrition in the Democratic Republic of the Congo

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07284095
Acronym
SANTE
Enrollment
40
Registered
2025-12-16
Start date
2026-02-01
Completion date
2026-08-31
Last updated
2025-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Malnutrition, Stunting of Growth

Keywords

Chronic Malnutrition, Stunting, Tenebrio Molitor, Food Security, Sustainable Foods

Brief summary

The goal of this clinical trial is to evaluate whether a dietary supplement based on Tenebrio molitor (mealworm flour) can improve nutritional status and biomarkers of micronutrient deficiency in children aged 2-10 years. The main questions it aims to answer are: • Does regular supplementation with Tenebrio molitor flour improve chronic malnutrition status Researchers will compare the intervention group (children receiving Tenebrio molitor flour supplement) with the control group (children receiving a traditional maize-soy flour supplement) to assess differences in biochemical and anthropometric outcomes after the intervention period. Participants will: * Participate in baseline and follow-up anthropometric and blood sample assessments (hemoglobin, albumin, zinc, iron, calcium, magnesium, vitamin A, folic acid, vitamin B12, prealbumin). * Consume a daily dietary supplement (either Tenebrio molitor flour or maize-soy flour) for the duration of the intervention. * Provide information on dietary intake and general health status through structured questionnaires administered by the research team.

Interventions

DIETARY_SUPPLEMENTTenebrio Molitor powder

The intervention consists of a daily dietary supplement made from Tenebrio molito powder, a sustainable and high-protein insect. Each participant in the intervention group will receive a pre-measured daily dose of Tenebrio molitor The supplement is designed to improve protein quality and micronutrient intake, particularly iron, zinc, and vitamin B12, in children aged 2-10 years. This intervention differs from traditional nutritional supplements by using Tenebrio molitor as a novel source of animal protein and micronutrients, contributing to sustainable food systems and child nutrition in low-resource settings.

DIETARY_SUPPLEMENTControl Group (Maize-Soy supplement)

The control supplement is a daily dietary mixture made from maize and soy flour, formulated to match the dose of the intervention supplement but without Tenebrio molitor protein. This preparation represents a conventional plant-based dietary supplement commonly used in nutritional support programs. It serves as an active comparator to assess the added nutritional and functional benefits of Tenebrio molitor flour in improving biochemical and anthropometric indicators of child nutrition.

Sponsors

Fundación Amigos de Monkole
CollaboratorUNKNOWN
Clinica Universidad de Navarra, Universidad de Navarra
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
2 Years to 10 Years
Healthy volunteers
No

Inclusion criteria

* Children diagnosed with chronic malnutrition (weight-for-height or BMI below -2 SD according to WHO standards). Children whose families agree to participate in the intervention and sign the informed consent form.

Exclusion criteria

* Children with severe acute illnesses that may interfere with the intervention. * Children with known allergies to the ingredients of the nutritional products provided.

Design outcomes

Primary

MeasureTime frameDescription
PrealbuminBaseline (Week 0) and 24 weeks of supplementation.Prealbumin levels will be measured to assess improvement in protein nutritional status among participants receiving Tenebrio molitor flour supplement compared with those receiving maize-soy flour supplement.
Height-for-Age z-scores (WHO Child Growth Standards)Baseline, 12 weeks and 24 weeksTo evaluate the effect of Tenebrio molitor supplementation on growth parameters in children. Scale range: z-scores less than or equal to -2 indicate stunting; less than or equal to -3 indicate severe stunting. Values close to 0 reflect adequate growth. High positive values (\>+2 or \>+3) indicate heights that are significantly above the average

Secondary

MeasureTime frameDescription
Change in Serum Vitamin B12 Concentration (pg/mL)From Baseline to 24 WeeksTo determine whether Tenebrio molitor flour improves serum Vitamin B12 levels compared to maize-soy flour.
Change in Serum Vitamin B9 (Folate) Concentration (µg/dL)From Baseline to 24 WeeksTo determine whether Tenebrio molitor flour improves serum Vitamin B9 (Folate) levels compared to maize-soy flour.
Change in Serum Iron Concentration (µg/dL)From Baseline to 24 WeeksTo determine whether Tenebrio molitor flour improves serum iron levels compared to maize-soy flour.
Change in Serum Calcium Concentration (mg/dL)From Baseline to 24 WeeksTo determine whether Tenebrio molitor flour improves serum Calcium levels compared to maize-soy flour.
Change in Serum Magnesium Concentration (mg/dL)From Baseline to 24 WeeksTo determine whether Tenebrio molitor flour improves serum Magnesium levels compared to maize-soy flour.
Change in Serum Vitamin A Concentration (µg/dL)From Baseline to 24 WeeksTo determine whether Tenebrio molitor flour improves serum Vitamin A levels compared to maize-soy flour.
Change in Serum Zinc Concentration (µg/dL)From Baseline to 24 WeeksTo determine whether Tenebrio molitor flour improves serum Zinc levels compared to maize-soy flour.

Countries

Democratic Republic of the Congo

Contacts

Primary ContactNerea Martín Calvo, PhD
nmartincalvo@unav.es+34 629 34 79 56
Backup ContactAndrea Aquino Blanco, Nutritionist
nmartincalvo@unav.es+34 692468366

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026